{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-249373","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2022-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.373817+00:00","generated_at":"2026-06-23T07:48:51.371592+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biomea Fusion EASD data: BMF-219 increases beta cell mass in human islets, improves glycemic control in rat T2D models","bullets":["BMF-219 increased beta cell mass in ex vivo human donor islets, first such translational data presented.","In ZDF rats, OGTT AUC reduced 54% vs vehicle (p<0.001) during treatment; 40% reduction maintained 2 weeks after washout (p<0.05).","In STZ rats, BMF-219 nearly doubled HOMA-B (+96%) and restored non-fasting glucose to near-normal by day 8.","BMF-219 reduced blood lipemic levels and body weight in both ZDF and STZ rat models.","Company remains on track to file IND for BMF-219 in type 2 diabetes in second half of 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-249373","json":"https://secwatch.observer/filing/0001193125-22-249373.json","markdown":"https://secwatch.observer/filing/0001193125-22-249373.md","text":"https://secwatch.observer/filing/0001193125-22-249373.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000119312522249373/0001193125-22-249373-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000119312522249373/d397871d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T07:48:51.371592+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}